This episode explores the shift towards continuous processing in the manufacturing of active pharmaceutical ingredients (APIs). The discussion outlines what continuous processing is, comparing it to traditional batch processing, and highlights the driving forces behind this evolution. The rise of enabling technologies like flow chemistry, quality by design (QbD), and the advantages they offer is discussed. The episode explores how flow chemistry and continuous processing enable the use of hazardous reactions safely and improve the efficiency of the reactions.

The episode also details the potential benefits of continuous processing, including increased efficiency, cost savings, improved product quality, enhanced safety, and faster development times. The discussion then turns to the regulatory aspects, noting the FDA's support for continuous manufacturing and the expectations for process understanding and control. Finally, the challenges associated with transitioning from batch to continuous production are explored, including upfront costs, the need for specialized expertise, and the importance of robust risk assessment. The final thoughts delve into what the means for the availability of medicines and needed skills for the pharmaceutical workforce.